Skip to main content

Burrows Scott L's Form 4 filing

Spyre Therapeutics, Inc. (SYRE) · filed Jul 2, 2026

Accession no.
0001636282-26-000088
Filed
Jul 2, 2026, 9:33 PM ET
Trade date
Jul 1, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $658.0K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Burrows Scott LCIK 0001853327Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 1, 2026Common StockMOption exerciseAcquired+7,500$14.50+$108,750105,494Direct
Jul 1, 2026Common StockSSaleDisposed−5,775$87.55−$505,601.2599,719Direct
Jul 1, 2026Common StockSSaleDisposed−1,725$88.37−$152,438.2597,994Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 1, 2026Common StockMOption exerciseDisposed−7,500$0.00$0352,357Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)